Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte BLOG

Improved Cell Screening Shows Promise for Leukemia Patients
MONDAY, APRIL 25, 2016
linkedin twitter facebook |  41Shares

In an article recently published In Vivo: Business & Medicine Report, author Mark Ratner writes about the growing use of high-throughput cell screening to identify combinations of therapeutics that are effective against cancer.


According to the article, new advances in sample handling technology and in computational biology have allowed scientists to generate more meaningful results from these high-throughput screens than was ever possible before. (Indeed, the strategy “failed to predict response to therapy” in the past, Ratner writes.) But new results, particularly from leukemia, indicate that cell-based screening has become a viable method for choosing which therapies to use for a particular patient.


The author points to acoustic liquid handling as one of the major innovations for cell screening. This approach “enables the transfer of nanoscale amounts of material, reduces errors in readouts of drug concentration and potency and provides more reproducible results,” Ratner explains. The nanoliter-scale of acoustic liquid handling reduces the cost of these assays and makes it possible to test more combinations of compounds than with traditional instruments.


Errors in drug potency are not uncommon in high-throughput screening. Ratner cites a 2014 Cancer Research paper finding that many of these problems are associated with pipette-based liquid handlers: serial dilutions and dispensing with these robots can introduce significant error in drug potency readings, far more significantly than is seen with acoustic liquid handlers, according to the study.


The article also includes lots of great information from scientists who use acoustic liquid handlers as well as from specific drug discovery examples. We think the article is well worth a read, so we’ve purchased reprint rights so you can read it here if you don’t have a subscription.